Blog
RSS FeedPosted by Michael Wonder on 10 Oct 2019
Elmiron bags draft NICE approval
10 October 2019 - NICE has published a draft final appraisal regarding Elmiron (pentosan polysulfate sodium) for bladder pain syndrome. ...
Posted by Michael Wonder on 09 Oct 2019
Scottish government readies ports to mitigate Brexit supply disruptions
9 October 2019 - Likely’ disruption to the supply of medicines and radiopharmaceuticals. ...
Posted by Michael Wonder on 05 Oct 2019
Drug pricing: Could Labour’s “radical” plan work?
4 October 2019 - A necessary reform or a threat to research? ...
Posted by Michael Wonder on 04 Oct 2019
Medicines that cannot be parallel exported from the UK
3 October 2019 - Sets out medicines that cannot be parallel exported from the UK because they are needed for UK ...
Posted by Michael Wonder on 03 Oct 2019
Drug firms 'colluded' to overcharge NHS by up to 1,800%
3 October 2019 - Three drug manufactures broke competition law by colluding to illegally boost the price of a vital ...
Posted by Michael Wonder on 03 Oct 2019
ABPI details Brexit plans at PIPA conference
3 October 2019 - The Association of the British Pharmaceutical Industry announced its latest Brexit contingency plans at the PIPA ...
Posted by Michael Wonder on 03 Oct 2019
NICE looks to company to ensure a new treatment for advanced breast cancer with significant unmet need is cost-effective
3 October 2019 - Draft guidance published today by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) ...
Posted by Michael Wonder on 02 Oct 2019
NICE numbers at 20: trends in deals
1 October 2019 - There have been a host of changes at the UK’s Health Technology Assessment agency – NICE ...
Posted by Michael Wonder on 02 Oct 2019
Advancing patient engagement
2 October 2019 - It’s widely accepted that seeking patient input into their health and care improves outcomes for them and ...
Posted by Michael Wonder on 28 Sep 2019
AveXis rules out EU compassionate use of SMA gene therapy, says Biogen option is available
27 September 2019 - Novartis’ AveXis unit has given its reasons for refusing to supply its spinal muscular atrophy gene ...
Posted by Michael Wonder on 27 Sep 2019
Industry shoots down Labour's plans to tackle 'extortionate' drug prices
26 September 2019 - Labour's promise to “take on pharmaceutical companies” which “deny life-saving and life-changing medicines to ill patients ...
Posted by Michael Wonder on 27 Sep 2019
With Brexit looming, what does the future hold for UK biosimilars?
26 September 2019 - If and when the United Kingdom leaves the European Union, the Medicines and Healthcare Products Regulatory Agency ...
Posted by Michael Wonder on 26 Sep 2019
Migraine drug not cost effective NICE says in final draft guidance
26 September 2019 - NICE has said that a new drug for preventing migraine is not a cost effective use of ...
Posted by Michael Wonder on 25 Sep 2019
NICE terminates another three assessments
25 September 2019 - NICE has terminated 11 assessments so far this year. ...
Posted by Michael Wonder on 25 Sep 2019
Labour Party takes aim at pharma, calls attention to Orkambi row
25 September 2019 - Proposal to introduce compulsory licensing faces industry criticism. ...